High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.

@article{Nath2016HighME,
  title={High melphalan exposure is associated with improved overall survival in myeloma patients receiving high dose melphalan and autologous transplantation.},
  author={Christa Ellen Nath and Judith Trotman and Campbell R Tiley and Peter Presgrave and Douglas Edgar Joshua and Ian B Kerridge and Yiu Lam Kwan and Howard Gurney and Andrew J. McLachlan and John W. Earl and Ian Nivison-Smith and Lihua Zeng and Peter A. Shaw},
  journal={British journal of clinical pharmacology},
  year={2016},
  volume={82 1},
  pages={149-59}
}
AIM High dose melphalan (HDM) and autologous stem cell transplantation (ASCT) retains a central role in the treatment of myeloma. The aim of this study was to determine whether HDM exposure (area under the concentration vs. time curve, AUC), is significantly associated with transplant outcomes. METHODS Melphalan concentrations were measured in six to 11 plasma samples collected after HDM (median 192 mg m(-) (2) ) to determine melphalan AUC for a total of 114 patients. Binary logistic… CONTINUE READING